CYCC- Wouldn't be surprised to see $2.5-$3.50 this week. Co is funded for beyond 2015, Phase 3 largest AML study ever and sapacitibine and seliciclib are gaining attention. could see some significant news ahead to send this up drastically given how low the float and share structure is.